This brand name is authorized in Spain
The drug MAXPIL contains one active pharmaceutical ingredient (API):
|
1
Finasteride
UNII 57GNO57U7G - FINASTERIDE
|
|
Finasteride is a competitive inhibitor of human 5ฮฑ-reductase, an intracellular enzyme which metabolises testosterone into the more potent androgen, dihydrotestosterone (DHT). In benign prostatic hyperplasia (BPH), enlargement of the prostate gland is dependent upon the conversion of testosterone to DHT within the prostate. Finasteride is highly effective in reducing circulating and intraprostatic DHT. Finasteride has no affinity for the androgen receptor. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D11AX10 | Finasteride | D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AX Other dermatologicals |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: ES | Centro de informaciรณn online de medicamentos de la AEMPS | Identifier(s): 70276 |
ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
